DekaBank Deutsche Girozentrale increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.7% during the second quarter, Holdings Channel reports. The firm owned 75,175 shares of the biopharmaceutical company’s stock after buying an additional 6,028 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Regeneron Pharmaceuticals were worth $38,399,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Korea Investment CORP increased its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the period. FNY Managed Accounts LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at $140,000. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the period. IFP Advisors Inc increased its position in Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares during the period. Finally, Wendell David Associates Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter valued at $204,000. Institutional investors own 66.70% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) opened at 460.08 on Friday. The company has a market capitalization of $48.78 billion, a PE ratio of 46.16 and a beta of 1.66. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55. The firm’s 50-day moving average price is $497.25 and its 200 day moving average price is $425.70.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.82 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.84 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/dekabank-deutsche-girozentrale-has-38-40-million-position-in-regeneron-pharmaceuticals-inc-regn.html.

Several research firms recently weighed in on REGN. BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the company a “hold” rating in a research report on Monday, May 15th. Leerink Swann reiterated an “outperform” rating and set a $580.00 target price (up from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Vetr downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 target price on the stock. in a research report on Monday, April 24th. UBS AG set a $489.00 target price on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 14th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of “Hold” and an average target price of $489.35.

In other news, major shareholder Sanofi purchased 136,050 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was acquired at an average price of $478.17 per share, for a total transaction of $65,055,028.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the sale, the executive vice president now owns 43,950 shares of the company’s stock, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,922 shares of company stock valued at $27,383,105. 10.40% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.